Prothena Corporation plc (PRTA) is a Biotechnology company in the Healthcare sector, currently trading at $10.82. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is PRTA = $26 (+138.4% upside).
Valuation: PRTA trades at a trailing Price-to-Earnings (P/E) of -2.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.01.
Financials: revenue is $10M, +8.2%/yr average growth. Net income is $244M (loss), growing at -36.2%/yr. Net profit margin is -2520.6% (negative). Gross margin is 61.8% (-25.7 pp trend).
Balance sheet: total debt is $14M against $280M equity (Debt-to-Equity (D/E) ratio 0.05, conservative). Current ratio is 7.72 (strong liquidity). Debt-to-assets is 4.2%. Total assets: $327M.
Analyst outlook: 20 / 28 analysts rate PRTA as buy (71%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 40/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 41/100 (Fail), Future 85/100 (Pass), Income 10/100 (Fail).
